RELMADA THERAPEUTICS, INC. — Director's Dealing 2019

Dec 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2019-12-24

Reporting Person: CASAMENTO CHARLES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-24	Common Stock	M	46484	$3.24	Acquired	46484	Direct
2019-12-24	Common Stock	M	21094	$4.60	Acquired	67578	Direct
2019-12-24	Common Stock	F	3706	$40.64	Disposed	63872	Direct
2019-12-24	Common Stock	F	2388	$40.64	Disposed	61484	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-24	Options to purchase common stock	$3.24	M	46484	Disposed	2019-12-26	Common Stock (3706)	Direct
2019-12-24	Options to purchase common stock	$4.6	M	21094	Disposed	2019-12-26	Common Stock (2388)	Direct

Footnotes

F1: Reflects 3,706 shares withheld at the market price of $40.64 per share to fund the cashless exercise of 46,484 options owned by Mr. Casamento, which cashless exercise was approved by the Board of Directors.

F2: Reflects 2,388 shares withheld at the market price of $40.64 per share to fund the cashless exercise of 21,094 options owned by Mr. Casamento, which cashless exercise was approved by the Board of Directors.

F3: The shares of common stock held by Mr. Casamento remain subject to the terms of the Lock-Up Agreement, dated November 21, 2019, between Mr. Casamento and Jefferies LLC, as representative of the several underwriters listed on Schedule A to the Underwriting Agreement, dated December 3, 2019, by and among Jefferies LLC, SVB Leerink LLC and Relmada Therapeutics, Inc.

F4: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.

F5: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.